Associated tags: MaRS Discovery District, CDMO, Laboratory, C3I, Genetics, Biotechnology, Pharmaceutical, Health, Science, Research, Other Manufacturing, Pulmonary fibrosis, Medical device, Lung, Cystic fibrosis, Clinical trial, Mediterranean Sea, Monogenic, Ontario Institute for Cancer Research, Inspiration, Regenerative medicine, AAV, EU
Locations: ONTARIO, NORTH AMERICA, CANADA, QUEBEC, EUROPE, UNITED STATES, MONTREAL
Retrieved on:
Wednesday, September 20, 2023
Other Manufacturing,
Research,
Genetics,
Clinical Trials,
Manufacturing,
Biotechnology,
Pharmaceutical,
Health,
Science,
Oncology,
CRISPR,
Laboratory,
Partnership,
C3I,
CDMO,
EU The Montreal-based CDMO C3i Center Inc is paving the way in the cell and gene therapy industry in North American and Canada as one of a few contract development and manufacturing organizations (CDMOs) to be producing in North America and for Europe.
Key Points:
- The Montreal-based CDMO C3i Center Inc is paving the way in the cell and gene therapy industry in North American and Canada as one of a few contract development and manufacturing organizations (CDMOs) to be producing in North America and for Europe.
- “We are proud of our team has worked very hard to be able to manufacture for EU clinical sites from our Montreal facility here in Canada.
- C3i manufactures from process development all the way to phase 3 with the expected goal of commercial manufacturing launch end of 2024.
- C3i has experience in autologous and allogeneic therapies using viral and non-viral methods as well as editing using CRISPR-based technologies.
Retrieved on:
Wednesday, March 15, 2023
Health,
Genetics,
Research,
Pharmaceutical,
Science,
Biotechnology,
AAV,
Regenerative medicine,
Pulmonary fibrosis,
Inspiration,
Ontario Institute for Cancer Research,
Monogenic,
Mediterranean Sea,
Clinical trial,
Cystic fibrosis,
Lung,
Medical device,
Medical imaging Inspire Biotherapeutics Inc. (“Inspire”), an emerging biotech company with a mission to create life-saving gene therapies for monogenic and acquired diseases of the lung, is poised to move its novel lung tropic AAV gene therapy into clinical validation.
Key Points:
- Inspire Biotherapeutics Inc. (“Inspire”), an emerging biotech company with a mission to create life-saving gene therapies for monogenic and acquired diseases of the lung, is poised to move its novel lung tropic AAV gene therapy into clinical validation.
- The AAVenger platform has demonstrated transduction and long-term expression in lung tissue without impact on other tissue types in disease-relevant animal models.
- The platform can be applied to treat cystic fibrosis, interstitial lung disease, pulmonary fibrosis, and other monogenic lung diseases.
- “Our lead indication is currently fatal in neonates – we are compelled to get this across the finish line!
